Evidence map›Paper›PMID 40863305›Full record

ReviewJournal of functional biomaterials2025

Polyphosphazene-Based Nanotherapeutics.

Sara Gutierrez-Gutierrez, Rocio Mellid-Carballal, Noemi Csaba, Marcos Garcia-Fuentes

Abstract readReview
In one paragraph

Review in Journal of functional biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sara Gutierrez-GutierrezDepartment of Pharmacology, Pharmacy and Pharmaceutical Technology, CiMUS Research Centre, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Rocio Mellid-CarballalDepartment of Pharmacology, Pharmacy and Pharmaceutical Technology, CiMUS Research Centre, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Noemi CsabaDepartment of Pharmacology, Pharmacy and Pharmaceutical Technology, CiMUS Research Centre, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Marcos Garcia-FuentesDepartment of Pharmacology, Pharmacy and Pharmaceutical Technology, CiMUS Research Centre, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.ORCID 0000-0002-6393-6469

Funding

Instituto de Salud Carlos III European Union NextGenerationEU/ EURONANOMED 3 AC21_2/00046Ministerio de Ciencia, Innovación y Universidades PID2021-124986OB-I00Ministerio de Educación y Formación Profesional FPU20/01525
6 · The paper itself

Abstract

Poly(organo)phosphazenes (PPZs) are increasingly recognized as versatile biomaterials for drug delivery applications in nanomedicine. Their unique hybrid structure-featuring an inorganic backbone and highly tunable organic side chains-confers exceptional biocompatibility and adaptability. Through precise synthetic methodologies, PPZs can be engineered to exhibit a wide spectrum of functional properties, including the formation of multifunctional nanostructures tailored for specific therapeutic needs. These attributes enable PPZs to address several critical challenges associated with conventional drug delivery systems, such as poor pharmacokinetics and pharmacodynamics. By modulating solubility profiles, enhancing drug stability, enabling targeted delivery, and supporting controlled release, PPZs offer a robust platform for improving therapeutic efficacy and patient outcomes. This review explores the fundamental chemistry, biopharmaceutical characteristics, and biomedical applications of PPZs, particularly emphasizing their role in zero-dimensional nanotherapeutic systems, including various nanoparticle formulations. PPZ-based nanotherapeutics are further examined based on their drug-loading mechanisms, which include electrostatic complexation in polyelectrolytic systems, self-assembly in amphiphilic constructs, and covalent conjugation with active pharmaceutical agents. Together, these strategies underscore the potential of PPZs as a next-generation material for advanced drug delivery platforms.

Indexed as

chemistrydrug-conjugatesmicellespharmaceutical propertiespolyelectrolytic complexespolymersomespoly(organo)phosphazenesPPZs

Identifiers

PMID40863305
PMCPMC12387868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.